U.S. patent application number 14/268373 was filed with the patent office on 2014-08-28 for tissue site markers for in vivo imaging.
This patent application is currently assigned to SenoRX, Inc.. The applicant listed for this patent is SenoRX, Inc.. Invention is credited to Fred H. Burbank, Stephen A. DeSantis, Michael L. Jones, Frank R. Louw, Paul Lubock, Richard L. Quick.
Application Number | 20140243675 14/268373 |
Document ID | / |
Family ID | 24883976 |
Filed Date | 2014-08-28 |
United States Patent
Application |
20140243675 |
Kind Code |
A1 |
Burbank; Fred H. ; et
al. |
August 28, 2014 |
TISSUE SITE MARKERS FOR IN VIVO IMAGING
Abstract
The invention is directed biopsy site markers and methods of
marking a biopsy site, so that the location of the biopsy cavity is
readily visible by conventional imaging methods, particularly by
ultrasonic imaging. The biopsy site markers of the invention have
high ultrasound reflectivity, presenting a substantial acoustic
signature from a small marker, so as to avoid obscuring diagnostic
tissue features in subsequent imaging studies, and can be readily
distinguished from biological features. The several disclosed
embodiments of the biopsy site marker of the invention have a high
contrast of acoustic impedance as placed in a tissue site, so as to
efficiently reflect and scatter ultrasonic energy, and preferably
include gas-filled internal pores. The markers may have a
non-uniform surface contour to enhance the acoustic signature. The
markers have a characteristic form which is recognizably artificial
during medical imaging. The biopsy site marker may be accurately
fixed to the biopsy site so as to resist migration from the biopsy
cavity when a placement instrument is withdrawn, and when the
marked tissue is subsequently moved or manipulated.
Inventors: |
Burbank; Fred H.; (Laguna
Niguel, CA) ; Lubock; Paul; (Monarch Beach, CA)
; Jones; Michael L.; (San Clemente, CA) ; Quick;
Richard L.; (Mission Viejo, CA) ; Louw; Frank R.;
(Carlsbad, CA) ; DeSantis; Stephen A.; (Mission
Viejo, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
SenoRX, Inc. |
Tempe |
AZ |
US |
|
|
Assignee: |
SenoRX, Inc.
Tempe
AZ
|
Family ID: |
24883976 |
Appl. No.: |
14/268373 |
Filed: |
May 2, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12787177 |
May 25, 2010 |
8718745 |
|
|
14268373 |
|
|
|
|
12460052 |
Jul 13, 2009 |
8224424 |
|
|
12787177 |
|
|
|
|
11238201 |
Sep 29, 2005 |
7565191 |
|
|
12460052 |
|
|
|
|
10823053 |
Apr 12, 2004 |
6993375 |
|
|
11238201 |
|
|
|
|
09717909 |
Nov 20, 2000 |
6725083 |
|
|
10823053 |
|
|
|
|
Current U.S.
Class: |
600/458 |
Current CPC
Class: |
A61B 2090/08021
20160201; A61B 6/12 20130101; A61M 37/0069 20130101; A61B 2090/3991
20160201; A61B 2090/3987 20160201; A61B 90/39 20160201; A61B 8/0833
20130101; A61B 2090/3925 20160201; A61B 2090/3908 20160201 |
Class at
Publication: |
600/458 |
International
Class: |
A61B 19/00 20060101
A61B019/00 |
Claims
1. An intracorporeal site marker for marking a selected site within
tissue of a patient's body, comprising: an ultrasound detectable
body including boundaries that contrast in acoustical impedance
with tissue of the selected site, so as to reflect ultrasound
during ultrasound imaging, the ultrasound detectable body having a
first end spaced apart from a second end; and a first migration
resistant tissue engaging element attached to the ultrasound
detectable body, and configured with a first linear portion that
cantilevers outwardly from the first end of the ultrasound
detectable body in a first direction, and configured with a first
curved end portion that extends from the first linear portion, the
first curved end portion having a first terminating free end
portion that extends in a second direction opposite to the first
direction back toward the ultrasound detectable body, the first
terminating free end portion being radially spaced apart from the
ultrasound detectable body.
2-41. (canceled)
42. The intracorporeal site marker of claim 1, wherein the first
terminating free end portion of the first curved end portion of the
first migration resistant tissue engaging element is longitudinally
spaced from the first end of the ultrasound detectable body.
43. The intracorporeal site marker of claim 1, comprising a second
migration resistant tissue engaging element attached to the
ultrasound detectable body, and configured with a second linear
portion that cantilevers outwardly from the second end of the
ultrasound detectable body in the second direction, and configured
with a second curved end portion that extends from the second
linear portion, the second curved end portion having a second
terminating free end portion that extends in the first direction
opposite to the second direction back toward the ultrasound
detectable body, and the second terminating free end portion being
radially spaced apart from the ultrasound detectable body.
44. The intracorporeal site marker of claim 43, wherein the second
terminating free end portion of the second curved end portion of
the second migration resistant tissue engaging element is
longitudinally spaced from the second end of the ultrasound
detectable body.
45. An intracorporeal site marker for marking a selected site
within tissue of a patient's body, comprising: a remotely
detectable body; and at least one migration resistant tissue
engaging element attached to the remotely detectable body, and
configured with a linear portion that cantilevers outwardly from
the remotely detectable body and a curved end portion that extends
from the linear portion, the curved end portion having a
terminating free end portion that extends in a direction back
toward the remotely detectable body and is radially spaced apart
from the remotely detectable body.
46. The intracorporeal site marker of claim 45, the at least one
migration resistant tissue engaging element including a first
migration resistant tissue engaging element having a first
terminating free end portion and a second migration resistant
tissue engaging element having a second terminating free end
portion, the first terminating free end portion and the second
terminating free end portion being oriented to face in opposite
directions.
47. The intracorporeal site marker of claim 45, the at least one
migration resistant tissue engaging element including a first
migration resistant tissue engaging element and a second migration
resistant tissue engaging element, wherein each of a first linear
portion of the first migration resistant tissue engaging element
and a second linear portion of the second migration resistant
tissue is attached to an external surface of the remotely
detectable body.
48. The intracorporeal site marker of claim 47, wherein the first
linear portion of the first migration resistant tissue engaging
element and the second linear portion of the second migration
resistant tissue are non-coaxial.
49. The intracorporeal site marker of claim 45, the remotely
detectable body having a first end spaced apart from a second end,
the at least one migration resistant tissue engaging element
including: a first migration resistant tissue engaging element
attached to the remotely detectable body, and configured with a
first linear portion that cantilevers outwardly from the first end
of the remotely detectable body in a first direction, and
configured with a first curved end portion that extends from the
first linear portion, the first curved end portion having a first
terminating free end portion that extends in a second direction
opposite to the first direction, and the first terminating free end
portion being radially spaced apart from the remotely detectable
body; and a second migration resistant tissue engaging element
attached to the remotely detectable body, and configured with a
second linear portion that cantilevers outwardly from the second
end of the remotely detectable body in the second direction, and
configured with a second curved end portion that extends from the
second linear portion, the second curved end portion having a
second terminating free end portion that extends in the first
direction opposite to the second direction, and the second
terminating free end portion being radially spaced apart from the
remotely detectable body.
50. An intracorporeal site marker for marking a selected site
within tissue of a patient's body, comprising: a cylindrical body
having a first end spaced apart from a second end; and a first
migration resistant tissue engaging element attached to the
cylindrical body, and configured with a first linear portion that
cantilevers outwardly from the first end of the cylindrical body in
a first direction, and configured with a first curved end portion
that extends from the first linear portion, the first curved end
portion having a first terminating free end portion that extends in
a second direction opposite to the first direction, and the first
terminating free end portion being radially spaced apart from the
cylindrical body.
51. The intracorporeal site marker of claim 50, wherein the first
terminating free end portion of the first curved end portion of the
first migration resistant tissue engaging element is longitudinally
spaced from the first end of the cylindrical body.
52. The intracorporeal site marker of claim 50, comprising a second
migration resistant tissue engaging element attached to the
cylindrical body, and configured with a second linear portion that
cantilevers outwardly from the second end of the cylindrical body
in the second direction, and configured with a second curved end
portion that extends from the second linear portion, the second
curved end portion having a second terminating free end portion
that extends in the first direction opposite to the second
direction, and the second terminating free end portion being
radially spaced apart from the cylindrical body.
53. The intracorporeal site marker of claim 52, wherein the second
terminating free end portion of the second curved end portion of
the second migration resistant tissue engaging element is
longitudinally spaced from the second end of the cylindrical body.
Description
RELATED APPLICATIONS
[0001] The present application is a Continuation-In-Part of U.S.
patent application Ser. No. 09/241,936, filed Feb. 2, 1999, and a
Continuation-In-Part of U.S. patent application Ser. No.
09/343,975, filed Jun. 30, 1999. Each of the above referenced
patent applications is incorporated by reference herein and the
benefit of the filing date of each application is hereby claimed
under 35 U.S.C. .sctn.1.20.
BACKGROUND OF THE INVENTION
[0002] In diagnosing and treating certain medical conditions, it is
often desirable to perform a biopsy, in which a specimen or sample
of the suspicious tissue is removed for pathological examination,
tests and analysis. As is known, obtaining a tissue sample by
biopsy and the subsequent examination are typically employed in the
diagnosis of cancers and other malignant tumors, or to confirm that
a suspected lesion or tumor is not malignant. The information
obtained from these diagnostic tests and/or examinations is
frequently used to devise a therapeutic plan for the appropriate
surgical procedure or other course of treatment.
[0003] In many instances, the suspicious tissue to be sampled is
located in a subcutaneous site, such as inside a human breast. Such
removal of tissue samples may be accomplished by open surgical
technique, or through the use of a specialized biopsy instrument
and techniques. To minimize surgical intrusion into patient's body,
it is often desirable to insert a small instrument, such as a
biopsy needle, into the body for extracting the biopsy specimen
while imaging the procedure using fluoroscopy, ultrasonic imaging,
x-rays, MRI or any other suitable form of imaging technique.
Examination of tissue samples taken by biopsy is of particular
significance in the diagnosis and treatment of breast cancer. In
the ensuing discussion, the biopsy and treatment site described
will generally be the human breast, although the invention is
suitable for marking biopsy sites in other parts of the human and
other mammalian body as well.
[0004] Periodic physical examination of the breasts and mammography
are important for early detection of potentially cancerous lesions.
In mammography, the breast is compressed between two plates while
specialized x-ray images are taken. If an abnormal mass in the
breast is found by physical examination or mammography, ultrasound
may be used to determine whether the mass is a solid tumor or a
fluid-filled cyst. Solid masses are usually subjected to some type
of tissue biopsy to determine if the mass is cancerous.
[0005] If a solid mass or lesion is large enough to be palpable, a
tissue specimen can be removed from the mass by a variety of
techniques, including but not limited to open surgical biopsy, a
technique known as Fine Needle Aspiration Biopsy (FNAB) and
instruments characterized as "vacuum assisted large core biopsy
devices".
[0006] If a solid mass of the breast is small and non palpable
(e.g., the type typically discovered through mammography), a
relatively new biopsy procedure known as stereotactic needle biopsy
may be used. In performing a stereotactic needle biopsy of a
breast, the patient lies on a special biopsy table with her breast
compressed between the plates of a mammography apparatus and two
separate x-rays or digital video views are taken from two different
points of view. A computer calculates the exact position of the
lesion as well as depth of the lesion within the breast.
Thereafter, a mechanical stereotactic apparatus is programmed with
the coordinates and depth information calculated by the computer,
and such apparatus is used to precisely advance the biopsy needle
into the small lesion. Depending on the type of biopsy needle(s)
used, this stereotactic technique may be used to obtain cytologic
specimens, e.g., obtained through FNAB or it may be used to obtain
histologic specimens e.g., obtained through coring needle biopsy.
Usually at least five separate biopsy specimens are obtained from
locations around the small lesion as well as one from the center of
the lesion.
[0007] The available treatment options for cancerous lesions of the
breast include various degrees of mastectomy or lumpectomy and
radiation therapy, as well as chemotherapy and combinations of
these treatments. However, radiographically visible tissue
features, originally observed in a mammogram, may be removed,
altered or obscured by the biopsy procedure. In order for the
surgeon or radiation oncologist to direct surgical or radiation
treatment to the precise location of the breast lesion several days
or weeks after the biopsy procedure was performed, it is desirable
that a biopsy site marker be placed in or on the patient's body to
serve as a landmark for subsequent location of the lesion site.
While current radiographic type markers may persist at the biopsy
site, an additional mammography generally must be performed at the
time of follow up treatment or surgery in order to locate the site
of the previous surgery or biopsy. In addition, once the site of
the previous procedure is located using mammography, the site must
usually be marked with a location wire which has a barb on the end
which is advanced into site of the previous procedure. The barb is
meant to fix the tip of the location wire with respect to the site
of the previous procedure so that the patient can then be removed
from the confinement of the mammography apparatus and the follow-up
procedure performed. However, as the patient is removed from the
mammography apparatus, or otherwise transported the position of the
location wire can change or shift in relation to the site of the
previous procedure. This, in turn, can result in follow-up
treatments being misdirected to an undesired portion of the
patient's tissue.
[0008] As an alternative or adjunct to radiographic imaging,
ultrasonic imaging and visualization techniques (herein abbreviated
as "USI") can be used to image the tissue of interest at the site
of interest during a surgical or biopsy procedure or follow-up
procedure. USI is capable of providing precise location and imaging
of suspicious tissue, surrounding tissue and biopsy instruments
within the patient's body during a procedure. Such imaging
facilitates accurate and controllable removal or sampling of the
suspicious tissue so as to minimize trauma to surrounding healthy
tissue.
[0009] For example, during a breast biopsy procedure, the biopsy
device is often imaged with USI while the device is being inserted
into the patient's breast and activated to remove a sample of
suspicious breast tissue. As USI is often used to image tissue
during follow-up treatment, it may be desirable to have a marker,
similar to the radiographic markers discussed above, which can be
placed in a patient's body at the site of a surgical procedure and
which are visible using USI. Such a marker enables a follow-up
procedure to be performed without the need for traditional
radiographic mammography imaging which, as discussed above, can be
subject to inaccuracies as a result of shifting of the location
wire as well as being tedious and uncomfortable for the
patient.
SUMMARY OF THE INVENTION
[0010] The invention is directed generally to devices and methods
of marking a biopsy site, so that the location of the biopsy cavity
is readily visible by ultrasonic imaging, as well as by
conventional imaging methods, such as x-rays. The biopsy site
marker of the invention is a persistent marker which may be
identified and located by ultrasound visualization.
[0011] The biopsy site markers of the invention have a body
conformation to enhance acoustical reflective signature or signal.
The body conformation may include boundaries of high contrast of
acoustic impedance to enhance ultrasound reflection. The markers
are readily detected by USI and present a substantial acoustic
signature from a marker with small physical dimensions or size.
Because of the high acoustic reflectivity of the markers of the
invention, the marker size may be reduced to dimensions determined
by the physical limits of the imaging system itself, e.g., the
ultrasound (US) beam width, without requiring a larger or excessive
marker size to reflect sufficient US energy to be noticeable.
[0012] In one embodiment, the biopsy site markers of the invention
have a characteristic body shape which is recognizably artificial
during medical imaging, so as to be readily distinguishable from
biological features within the marked tissue. In particular, the
markers are readily distinguishable in the various imaging
procedures from diagnostically important tissue features, such as
lines of calcifications which frequently are signs for a developing
malignancy. The marker body shape may have one or more distinct
features which may be visualized in different marker orientations.
The shape may correspond to a generally known symbol, so a to
enhance recognition.
[0013] In another embodiment, the markers of the invention have a
body conformation to enhance the acoustic signature or signal, so
that the body has high acoustic reflectivity when situated in
tissue. The acoustic reflective signature of the markers depends on
a number of factors. The marker may comprise a composition which
presents at least one boundary of high contrast in acoustic
impedance to incident US energy, effectively reflecting the US
energy to be received by the imaging system. Acoustic impedance
(AI) of a material is equal to the product of the characteristic
density (.rho.) of the material and the acoustic velocity (c) in
the material, (i.e., AI=.rho..times.c). As an incident US beam
encounters a boundary with a large change in acoustic impedance
(e.g., at the marker surface or internal to the marker), much of
the US energy is effectively reflected.
[0014] Different types of tissue have a wide range of acoustical
impedance, for example lung tissue with high air content having low
acoustical impedance as compared to bone tissue having high mineral
content. However, for uses such as biopsy site marking in typical
mammalian soft tissue of high aqueous content, the typical range of
tissue acoustical impedance is intermediate these extremes. The
composition and body conformation of the markers of the invention
may be selected so as to provide boundaries of high contrast of
acoustic impedance with respect to the particular tissue site of
use.
[0015] In an embodiment of the invention, the marker may have a
composition in which a base or matrix substance of the marker body
(e.g., stainless steel) has an acoustic impedance substantially
higher than the tissue at the marked body site. For example,
typical bio-compatible metal materials, such as stainless steel,
titanium, platinum and the like, generally have acoustic impedance
values in the range of 15 to more than 30 times that of typical
soft tissue of high aqueous or fatty content. The high acoustic
impedance of the marker body base material relative to the
surrounding tissue presents a reflective interface to an incident
US beam.
[0016] A suitable marker body composition with acoustic impedance
substantially higher than the tissue at the marked body site is
316L stainless steel. Other alternative compositions, such as
compositions of bio-compatible metals, ceramics, metal oxides or
polymers, or composites or mixtures of these materials, may be
suitable. The marker body may also be radio-opaque.
[0017] In another embodiment of the invention, the marker may have
a composition in which marker body includes one or more (preferably
a large plurality) of internal bounded spaces, such as voids,
pores, discontinuities, inclusions, bubbles and the like. These
internal spaces preferably contain or entrain air or other
gases.
[0018] Air has an extremely low acoustic impedance relative to the
marker body base or matrix substance. This is true even for matrix
materials which themselves have acoustic impedance close to that of
the surrounding tissue (e.g., some bio-compatible polymers). The
marker body presents internal boundaries of high contrast in
acoustic impedance, i.e., at the boundary between the matrix and
each internal air-filled space. The marker body thus presents
plurality of reflective interfaces to an incident US beam.
[0019] Alternatively or in combination with to the materials of
high acoustic impedance described above, a marker body with
internal voids or air spaces may, if desired, comprise a matrix or
base composition which has an acoustic impedance close to that of
the tissue at the marked body site, since the air or other gas
within the internal spaces provides a dramatic contrast to the
matrix material. Suitable bio-compatible materials include
polyethylene, polytetrafluoroethylene, PEBAX (made by Autochem
Corp.), and the like.
[0020] The body matrix material can have a hydrophobic composition
or be treated to be hydrophobic. The surface area bounding internal
open-cell pores should be hydrophobic so as to resist the
displacement of air or other gases in the pores by aqueous fluid
from the surrounding tissue, particularly in the case of relatively
large pore or space size.
[0021] In some embodiments of the invention, the markers can
include surface characteristics which enhance the acoustic
signature and improve visibility under US imaging, as opposed to a
smooth, rounded body surface. In order to provide enhanced
ultrasound imaging visibility from all directions of US
impingement, the biopsy marker can have a plurality of reflective
external surfaces. By making the surface of an object lobulate,
multifaceted or otherwise irregular, more reflective surfaces are
created, and a brighter acoustic signature is achieved.
[0022] For example, a smooth solid sphere provides at least some
reflective surface oriented in each direction, but the reflection
is achieved over a small portion to the area of the sphere, thus
producing an unremarkable acoustic signature. In contrast, an
object of the same composition and average diameter as the sphere,
but with a highly irregular surface texture, a much brighter
acoustic signature or signal is achieved. Thus, the by providing
more reflective surfaces of differing or random orientation, the
markers appears brighter in US imaging.
[0023] The signal-enhancing body conformation may include
non-smooth surface texture, such as a porous, frosted, matte,
pitted, peened, or scratched surface texture, and the like. The
body conformation may also include a multi-element surface contour,
such as a faceted, multi-planar, lobulate, coiled, grooved, folded,
or inlet surface contour, and the like. Such external body
conformations may be used in combination with one another and in
combination with the internal discontinuities or air spaces
described above.
[0024] The body length, diameter or other characteristic scale
dimensions of some embodiments of the biopsy marker of the
invention may be of a range of sizes. The optimum dimensions of the
body will depend upon the specific selected factors which influence
acoustic signature as described herein, such as material impedance,
surface contours, surface texture, and internal conformation. In
addition, the optimum size may depend upon such factors as the type
of ultrasound imaging/visualization system used, its imaging
resolution, the operating ultrasound frequency, and the biophysical
nature of the tissue of interest.
[0025] The body dimensions may be selected so as to be large enough
to provide a distinct, recognizable marker image within the tissue
biopsy site, when visualized under the particular imaging system
and operating conditions of use. The body dimensions may also be
selected to be small enough to avoid masking or obscuring
diagnostically important tissue features. Thus different marker
dimensions may be selected to suit particular biopsy site tissue
types, and to suit particular known and future medical imaging
equipment.
[0026] In terms of over-all size, it is desirable that the marker
have at least one dimension which is about as large as or greater
than the beam width of the USI system with which it is to be
visualized. Typically, for current USI systems, the marker will
have at least one dimension of about 1 mm or greater, and
preferably of at least about 1.5 mm.
[0027] In addition, for convenience in applying the marker to the
tissue site, the specific marker dimensions and shape may be
selected so as to accommodate the dimensions of a particular known
or novel biopsy needle device or sampling apparatus, while still
achieving a distinct and recognizable marker image under medical
imaging as placed at the tissue site. By selecting a marker size
and shape to fit within the internal diameter of a biopsy needle or
sampling device, the marker may be implanted or applied to the
biopsy cavity during the course of the biopsy procedure, following
sample recovery but prior to removal of the biopsy device. For
example, the marker of the invention may have a size and shape
selected to permit application of the marker through the hollow
interior space of a vacuum assisted large core biopsy device, such
as is commercially available from Johnson and Johnson, Ethicon
Endosurgery Division. The small physical size of the markers of the
invention relative to their acoustic reflectivity permits fitting
the markers to a wide variety of biopsy devices.
[0028] In terms of the size of features, including external or
internal pores, texture features, facets and the like, it is
preferable that these features have a characteristic dimension
approximately equal to or exceeding the wavelength of the US beam
of the imaging system. For example, with current imaging systems,
for a marker with internal air-filled pores, the pore size is
typically from about 1 micrometer to 100 micrometers and preferably
from about 5 micrometers to 40 micrometers, to provide high
reflectivity of the incident US energy.
[0029] Optionally, some embodiments of the biopsy site marker of
the invention may have elements which assist in accurately fixing
the marker to the biopsy site so as to resist migration from the
biopsy cavity. Such migration can occur when a placement instrument
is withdrawn, and when the marked tissue is subsequently moved or
manipulated, as for example when a breast is decompressed and
removed from the mammography apparatus. In one embodiment, one or
more tissue engaging structures or haptic elements are mounted or
affixed to the main marker body, so as to resist movement or
migration of the marker from the biopsy site in which it has been
implanted during use.
[0030] In another embodiment, the biopsy site marker may comprise a
pellet-shaped element which encapsulates the high impedance marker
body, and assists in resisting migration. The encapsulating pellet
may be of a composition, such as gelatin, which is absorbed or
dissipated over time, leaving the persistent marker body at the
tissue site. In yet another embodiment, the marker body (and/or the
optional encapsulating element) may include an adhesive component
to cause the marker body (or encapsulating element) to adhere to
adjacent tissue within the biopsy site.
[0031] A method of the invention for marking a tissue site of
interest can include implanting one or more of the markers of the
invention, such as one of the exemplary marker embodiments
described herein, in or adjacent to a tissue site of interest,
e.g., within a biopsy cavity. The marker may then be visualized in
situ, such as for purposes of subsequent medical and surgical
procedures. The visualization may be by various known medical
imaging systems and methods, and in particular may be visualized by
known USI systems.
[0032] Biopsy markers of the invention can be deposited in
accordance with the various methods and techniques utilized in the
state of the art. One technique of applying the biopsy markers of
the invention is to place or deposit them in a biopsy cavity that
is created with a vacuum assisted large core biopsy device. An
applicator particularly suitable for insertion of the biopsy site
markers of the invention is described below. However, it should be
understood that the biopsy markers of the invention can be used
without the exemplary applicator device described herein. The
biopsy marker applicator disclosed in co-pending application Ser.
No. 09/343,975 filed Jun. 30, 1999, may be used to apply the
markers of the current invention to a biopsy site. The dimensional
size of the applicator device (particularly the inside diameter)
may be adjusted to correspond to a selected diameter or
characteristic dimension of the biopsy site marker embodiment of
the present invention.
[0033] These and other advantages of the invention will become more
apparent from the following description when taken in conjunction
with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0034] FIG. 1 is a perspective view of a human breast partially cut
away having a lesion from which a biopsy specimen has been removed,
and showing a marker applicator syringe and introduction cannula
operatively positioned for introduction of a biopsy site marker
embodying features of the present invention into the cavity created
by removal of the biopsy specimen;
[0035] FIGS. 2A-2E show exemplary conformations and shapes of
sintered or porous metal site marker embodiments of the invention,
FIG. 2A showing a sintered body having irregular pores, FIG. 2B
showing a bubble-filled marker body, FIG. 2C showing a
cylindrical-shaped marker, FIG. 2D showing a cruciform-shaped
marker and FIG. 2E showing a polyhedral shaped marker.
[0036] FIG. 3 shows a marker having the shape of a Greek
letter.
[0037] FIG. 4 shows an example of the alternative coil-shaped
embodiment of the marker of the invention;
[0038] FIG. 5 shows an example of the alternative spheriod
embodiment of the marker of the invention;
[0039] FIG. 6 is a schematic view (scale exaggerated for clarity)
of an exemplary biopsy tissue site, in this case a human breast,
showing a biopsy cavity of the type obtained by a known type of
vacuum assisted large core biopsy sampler device, into which a
biopsy marker or markers embodying features of the invention are
deposited by a marker applicator device inserted through the outer
cannula of the large core biopsy sampler.
[0040] FIG. 7 shows schematically an embodiment of the invention
including one or more haptic elements and/or an adhesive component,
for resisting migration of the marker within the tissue.
[0041] FIG. 8 shows schematically an embodiment of the invention
including an encapsulating element and optional adhesive component,
for resisting migration of the marker within the tissue.
[0042] FIG. 9A is a schematic view of a biopsy sampler device at a
tissue site with an alternative marker delivery system.
[0043] FIG. 9B is a perspective view of the petalled distal end of
the delivery device shown in FIG. 9A.
[0044] FIG. 9C is a perspective view of the distal end of the
delivery device shown in FIG. 9A with a marker exiting the petalled
distal end.
[0045] FIG. 10 is a perspective view of an alternative marker
having a gel body with a radiopaque collar disposed about the gel
body.
DETAILED DESCRIPTION OF THE INVENTION
[0046] The following detailed description, and the accompanying
drawings to which it refers are provided for purposes of
exemplifying and illustrating representative examples and
embodiments of the invention only, and are not intended to limit
the scope of the invention in any way, and do not exhaustively
illustrate and describe all possible embodiments and configurations
in which one or more features of the present invention may take
physical form.
[0047] All patents and patent applications cited in this
specification are herein incorporated by reference as if each
individual patent or patent application were specifically and
individually indicated to be incorporated by reference.
[0048] FIG. 1 shows the use and insertion into a biopsy site of any
one of the biopsy site marker embodiments of the invention
described herein. FIG. 1 is a perspective view of a human breast 2
having a lesion 3 from which a biopsy specimen has been removed,
thereby forming a biopsy cavity 4 within the lesion 3, into which a
biopsy site marker 10 of the of the present invention is implanted.
The figure shows an outer cannula 12 with the distal end thereof
operatively positioned within the biopsy site 4. The outer cannula
12 has been inserted percutaneously into the lesion 3 and a biopsy
needle (not shown) has been passed through the outer cannula 12 and
used to remove a biopsy specimen from the center of the lesion.
[0049] Syringe-like marker application device 13 includes a marker
introduction tube or inner cannula 14. After removal of the biopsy
needle (not shown), the marker introduction cannula 14 has been
passed through the outer cannula 12 such that inner cannula distal
end 14d is located within the biopsy cavity 4, the marker 10 being
housed within cannula 14. Piston 15 of marker applicator 13 has an
extension 16 which passes through the interior of inner cannula 14.
Upon depressing piston 15, extenuation 16 pushes marker 10 outward
through an opening 17 in the tip 14d of inner cannula 14 into the
cavity 4.
[0050] The outer cannula 12 may be an outer tube element of a
conventional vacuum assisted large core biopsy device, which has
been left in place to assist in site marker application following
biopsy sample recovery. One example of a applicator syringe device
13 is described in further detail below with respect to FIG. 5.
[0051] FIGS. 2A, 2B, 2C, 2D and 2E show exemplary internal
conformations and shapes of the sintered or porous site marker
embodiments of the invention 20a-20e respectively.
[0052] FIGS. 2A and 2B show schematic cross sections of a
alternative porous or sintered marker body embodiments. FIG. 2A is
a cross section of a sintered site marker embodiment 20a. The
matrix or base material 21 encloses a plurality of irregular shaped
pores 22 distributed within the body 20a, preferably throughout the
body volume. The term "sintered" will be used to describe the
porous body conformation, it being noted that conventional methods
of production other than sintering may be employed to produce a
material containing internal voids, pores, discontinuities,
inclusions, bubbles and the like.
[0053] The pores 22 may be open celled, in which the pores 22
generally intersect or communicate with one another and the marker
body exterior, which may give the body surface 23 a pitted texture
on the scale of the pore size. Alternatively, the pores may be
closed celled, in which the pores 22 generally do not intersect one
another or the exterior. In the event that the pores 22 communicate
with the marker exterior 23, the matrix material 21 is preferably
hydrophobic (or treated to have hydrophobic surfaces) to resist
displacement of air entrained in pores 22.
[0054] The base or matrix composition 21 has may be of high
acoustic impedance relative to the surrounding tissue (not shown).
Sintered metal material may be shaped and sintered from
commercially available metallic powders comprising a metal or
mixtures of metals, using conventional sintering and forming
techniques to produce body of selected shaped, and selected pore
size and surface texture, so as to enhance acoustic reflectivity.
The porosity of the sintered metal provides an irregular surface
texture as well as internal voids. A suitable bio-compatible
material is sintered 316L stainless steel, and suitable sintered
stainless steel stock is commercially available in various forms,
for example from the Mott Corporation. The sintered stock may be
economically cut and shaped by conventional methods. Sintered
stainless steel stock is commercially available with controlled
pore size, selectable over a range of pore sizes. The pores 22 of
the sintered body 20a may vary over a range of pore sizes, and is
typically from about 1 micrometer to 100 micrometers and preferably
from about 5 micrometers to 40 micrometers.
[0055] In addition to sintered metal, alternative bio-compatible,
impedance materials may be included or substituted, such as
ceramics, metal oxides, polymers or composites/mixtures of these
materials, which may be configured to have a generally distributed
internal porosity and porous surface texture. Thus, the marker body
20a may comprise a matrix or base composition 21 which has an
acoustic impedance close to that of the tissue at the marked body
site, since the air or other gas within the pores or internal
spaces 22 provides a dramatic contrast to the matrix material 21.
Suitable bio-compatible materials include polyethylene,
polytetrafluoroethylene, PEBAX (made by Autochem Corp.), and the
like. Such porous materials may be formed by conventional methods,
such as heat bonding of polymer powders, extrusion and the
like.
[0056] FIG. 2B is a schematic cross section of an alternative site
marker embodiment 20b. The matrix or base material 24 encloses a
plurality of inclusions, suspended particles or bubbles 25
distributed within the body 20b, preferably throughout the body
volume. The inclusions 25 may be low-density or gas-filled
particles, such as foamed-in-place bubbles, micro-beads, expanded
beads, and the like, which have an acoustic impedance substantially
lower than the matrix material 24. The matrix material 24 may as in
the example of FIG. 2A.
[0057] FIGS. 2C and 2D show exemplary shapes of the sintered or
porous site marker embodiments of the invention 20c and 20d
respectively. FIG. 2C shows schematically a cylindrical sintered
marker 20c. The marker 20c comprises a generally cylindrical body
having a diameter d and length l. The body may have diameter d of
from 0.5 to 5 mm, and preferably about 1.5 mm. The length l may be
from about 1 diameters to about 10 diameters, and preferably from
about 5 to 7 diameters. This biopsy site marker produces a
distinct, recognizable, marker image of artificial appearance when
implanted at a depth of about 2 to 4 cm in human breast tissue, and
visualized by a commercially available Accuson 128 US imaging
system with an L7 transducer.
[0058] FIG. 2D illustrates a marker body 20d having a polyhedral
form of multiple intersecting flat surfaces 26, 27 and 28.
[0059] FIG. 2E shows a cruciform shaped marker 20e having cruciform
cross-section having four longitudinal fin-like portions 29, which
may be aligned at right angles to one another and joined at the
longitudinal central axis 30 providing a selectable number of side
facets (e.g., hexagonal cross-section). Optionally, medial web
portions 31 may span laterally and join between adjacent fins 29,
the webs 31 preferably being aligned perpendicularly to the fins
29. In the example shown, there are four such web portions 31
positioned at about mid-length of the body 20e, so that each fin 29
is joined by a pair of webs 31, one on each side, to each adjacent
fin. Thus, the planes of the intersecting fins and webs form a
pattern of eight mutually-perpendicular "corner reflectors" 32. The
length l and characteristic cross-section dimension c may be as
described with respect to the embodiments of FIGS. 2C and 2D.
[0060] FIG. 3 illustrates yet another alternative where the marker
body is shaped to have the form, under ultrasound or radiological
visualization, preferably both, of a familiar symbol or letter, to
by easily recognizable as an artificial shape which is the
lower-case Greek letter Gamma (.gamma.), which when visualized in a
biopsy site bears a resemblance to a familiar
breast-cancer-awareness symbol.
[0061] FIG. 4 shows schematically an alternative coil marker 30 of
the invention. The marker 30 comprises a generally helical
coil-like body formed from one or more lengths of fine wire and/or
fiber 31. The coil 30 has a generally cylindrical overall form. As
with the other biopsy site marker embodiments of the invention, the
optimum dimensions of the coil shaped marker embodiment will depend
on such factors as the type of visualization system used, its
imaging resolution, and the physical nature of the biopsy tissue
region. The coil length l and diameter d may be of a range of
sizes, selected so as to be large enough to provide a distinct,
recognizable ultrasound marker image within the tissue biopsy site,
and small enough to avoid masking or obscuring diagnostically
important tissue features. For example, the coil diameter d may be
from 0.5 to 5 mm, and preferably about 1.5 mm. The coil length l is
typically from about 1 coil diameters to about 10 coil diameters,
and preferably from about 5 to 7 coil diameters.
[0062] The helical turns of the coil provide a body surface contour
including a outer helical groove 32 and inner helical groove 33 on
the coil surfaces (more than one such groove for a multiple helix).
The grooved coil body surface includes a plurality of lobes and
crevices on the exterior of the coil which enhance acoustic
reflectivity. In addition the similarly lobed internal surfaces of
the coil provide additional reflectivity. Optionally, the coil may
be given a "frosted" or textured surface, such as by particle
blasting in the manner of the spheroid marker described above. A
uniform coil embodiment has a shape which is markedly artificial in
appearance under conventional visualization methods, and is not
easily confused tissue features of biological origin.
[0063] The coil may comprise a fine wire 31 of a material of high
acoustic impedance relative to the tissue of the site, and may
optionally be radio-opaque. Suitable materials are biologically
compatible metals, such as stainless steel, titanium, platinum,
palladium, alloys thereof and the like. The coil may alternatively
comprise a composite of different materials, such as a composite of
metal and polymeric materials. The coil may be wound about a
central core of the same or different composition. Coil stock of
suitable material, helical form and diameter is available
commercially, and may be cut to a selected length by conventional
means. A suitable material is 316 L stainless steel surgical
embolization coil currently used in arterial embolism repair
procedures, e.g., Cook 4 mm diameter embolization coil
MWCE-25-2.5-4 of 316L stainless steel and Dacron. Other suitable
embolization coil stock is available in a range of coil diameters.
This biopsy site marker produces a distinct, recognizable marker
image as implanted at a depth of about 2 to 4 cm in human breast
tissue, when visualized by a commercially available Accuson 128 US
imaging system with an L7 transducer.
[0064] FIG. 5 shows schematically the alternative spheroid marker
40 of the invention having a generally spherical body 40. Note that
the porous or sintered marker embodiments of FIGS. 2A-2D may be
spherical also. However, the embodiment of FIG. 5 is a non-porous
example, and the biopsy site marker 40 comprises a high acoustic
impedance, biologically compatible material, such as 316 L
stainless steel and titanium, or radiopaque metals such as
platinum, palladium, or the like. Non-spherical shaped bodies may
be used, however, metallic spheres of suitable materials are
readily commercially available, and have a shape which is markedly
artificial in appearance under conventional visualization methods,
i.e., not easily confused tissue features of biological origin.
[0065] The generally spherical body may have a diameter d selected
so as to be large enough to provide a distinct, recognizable
ultrasound marker image within the tissue biopsy site, and small
enough to avoid obscuring tissue features. As with the other biopsy
site marker embodiments of the invention, the optimum size of the
sphere will depend on such factors as the type of visualization
system used, its imaging resolution, and the physical nature of the
biopsy tissue region. For example, the sphere diameter d is
typically be from about 1 mm to about 4 mm, and preferably from
about 1.5 mm.
[0066] The spherical body 40 may include a pitted, matte, peened or
frosted surface texture 41, which may be produced by conventional
particle blasting or peening techniques. For example, the sphere
may be blasted with glass beads of about 100 micrometer diameter to
produce a frosted surface. In another example, the sphere may be
blasted with aluminum oxide abrasive particles of about 25
micrometer diameter to produce a frosted surface. The frosted
surface 41 thus produced provides enhanced acoustic reflectivity in
comparison to the untreated, smooth sphere. Other conventional
texturing, pitting or faceting methods may alternatively be used to
produce a frosted or irregular surface texture.
[0067] This biopsy site marker produces a distinct, recognizable
marker image of artificial appearance when implanted at a depth of
about 2 to 4 cm in human breast tissue, and visualized by a
commercially available Acuson 128 US imaging system with an L7
transducer.
[0068] FIG. 6 shows schematically in cut-away section an exemplary
marker applicator device 50 configured to be operated in
association with a conventional vacuum assisted large core biopsy
device 6. The dimensional size of the applicator device
(particularly the inside diameter) may be adjusted to correspond to
the selected diameter or characteristic dimension of the biopsy
site marker to be deposited. In this connection it should be
understood that the biopsy markers of the invention can be used
without this applicator, and can be deposited in accordance with
the various methods and techniques utilized in the state of the
art.
[0069] The applicator 50 comprises an elongated cylindrical body 52
which has an outer diameter selected so that it fits, and may be
inserted through, the outer cannula 7 of vacuum assisted large core
biopsy device 6. As shown in FIG. 6, the outer cannula 7 is
inserted through the biopsy incision into the biopsy cavity 4
previously formed in the patient's tissue site 8, e.g., a human
breast in the case of a breast biopsy.
[0070] The cylindrical body 52 has an interior cavity and a piston
54 that fits and slides back and forth in the elongated cylindrical
body 52. The proximal end of the outer cannula 7 may be provided
with rectangularly shaped handle 56 the orientation of which
indicates to the operator the orientation of the opening 9 provided
in the distal end of the cannula 7. The cylindrical body 52 may
have an enlarged finger disk or handle 57 at its outer (exterior to
the patient) end which permits a user (not shown) to operate or
move the piston 54 within the cylinder 52 of applicator 50. the
orientation of the elongated finger disk 57 indicates the
orientation of the opening 58 of body 53 adjacent its other, closed
end 59 (internal within biopsy cavity). The opening 58 is
configured to form a ramp in the side of the tube 52.
[0071] In this connection it should be understood that the selected
dimensions of the tube 52 are coordinated with the dimensions of
the piston 54 and with the cannula 7 of the vacuum assisted large
core biopsy device 6, thus permitting the tube 52 to both fit
within cannula 7 and to contain one or more markers of the
invention 10 within the inside diameter of cylinder 52. The
cylinder or tube 52 and the piston 54 may be made from any
appropriate medical grade plastic material, such as high density
polyethylene or PEBAX, made by the Autochem Corporation.
[0072] In one method of implanting the biopsy markers 10 of the
present invention, the tube 52 is loaded with one or more of
markers 10. The markers 10 may be any of the embodiments of the
invention described above, and is shown schematically as a
cylindrical object. Optionally, in addition to the markers 10,
pellets composed of various other materials may be inserted along
with one of the embodiments of the biopsy markers of the present
invention described herein. For example, gelatin pellets of the
type disclosed in our above referenced co-pending application Ser.
No. 09/343,975 may be inserted in conjunction with the biopsy
markers 10 of the present invention.
[0073] With the markers 10 in the tube 52 and the tube 52 and
cannula 7 inserted into the biopsy site 4, the opening 58 in the
cylinder 52 is moved into alignment with the opening or port 9 of
the in the internal end of cannula 7 of biopsy sampler 6. The
piston 54 is pressed inward by the operator so that the marker or
markers 10 are expelled from the tube 52 through the ramp shaped
opening 58 as the piston 54 is pushed into the cylinder or tube 52.
The markers 10 are thereby extruded through opening 59 and port 9
into the biopsy cavity 4. The applicator 50 and biopsy device 6 are
subsequently withdrawn.
[0074] FIG. 7 shows schematically an alternative marker 60 of the
invention including one or more optional tissue-engaging or haptic
elements 62 for resisting migration of the marker from the biopsy
site. An exemplary cylindrical marker body 10 is shown, although
each embodiment of the biopsy site marker of the invention
described above may optionally comprises one or more such tissue
engaging structures. The haptic elements 62 may comprise an
wire-like material fixed to the marker body 10 at the proximal
haptic end 64 and extending outward from the marker body 10. The
haptic 62 may be looped back at its hook-like terminal end 66.
[0075] The haptic 62 assists in resisting migration of the marker
from the biopsy cavity, during initial placement, i.e., it engages
the adjacent tissue to resist being sucked back towards the
applicator when the applicator is withdrawn. The haptic also
resists migration during later movement, flexure or manipulation of
the tissue surrounding the biopsy site, such as when a patient's
breast is decompressed upon removal from a mammography device.
Optionally, the marker body 10 may include an adhesive component 68
coated onto its surface to cause the marker body to adhere to
adjacent tissue within the biopsy site.
[0076] FIG. 8 shows schematically the alternative marker 70 of the
invention including an encapsulating element 72 and optional
adhesive layer or component 74, for resisting migration of the
marker within the tissue. An exemplary cylindrical marker body 10
is shown, although each of the biopsy site marker of the invention
described above may optionally comprise a pellet-shaped
encapsulating element.
[0077] The pellet-shaped encapsulating element 72 is disposed
surrounding the marker body 10 and may fully or partially enclose
the marker body. The encapsulating element 72 may be of lower
impedance than the metallic marker body 10. Suitable materials are
gelatin or reconstituted collagen material, polymers, or mixtures
or composites thereof. An optional adhesive component 74 is shown
coating the external surface of the encapsulating element, but may
be included within the composition the encapsulating element
72.
[0078] FIG. 9A illustrates an alternative device 80 for delivering
markers to a biopsy site which includes an elongated tube 81, a
handle 82 on the tubes proximal end and a closed distal end having
a plurality of leafs or petals 83 as shown in more detail in FIG.
9B. As shown in FIG. 9C, the petals 83 open up to allow a marker 84
to be discharged into the biopsy site 85 as shown in FIG. 9C. The
device 80 has an elongated plunger or piston 86 slidably disposed
within the tube 81 for pushing one or more markers 84 through the
petalled distal end by pressing on the knob 87 on the proximal end
of the shaft 86. The orientation of the body 88 on the shaft 86
gives the operator an indication of the orientation of the shaped
distal end 89.
[0079] FIG. 10 illustrates an alternative marker 90 which has an
elongated cylindrically shaped body of gel 91 surrounded with a
metallic band 92 which is preferably formed of radiopaque material.
The band 92 may completely or only partially surround the body of
gel 91.
[0080] In any of the above-described embodiments of the invention,
the marker body (and/or the optional encapsulating element) may
include an adhesive component to cause the marker body (or
encapsulating element) to adhere to adjacent tissue within the
biopsy site. The adhesive component may comprise a biocompatible
adhesive, such as a polyurethane, polyacrylic compound,
polyhydroxymethacrylate, fibrin glue (e.g., Tisseal.TM.), collagen
adhesive, or mixtures thereof.
[0081] While particular forms of the invention have been
illustrated and described, it will be apparent that various
modifications can be made without departing from the spirit and
scope of the invention. Accordingly, it is not intended that the
invention be limited to the specific embodiments illustrated. It is
therefore intended that this invention to be defined by the scope
of the appended claims as broadly as the prior art will permit, and
in view of the specification if need be.
* * * * *